

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Volume 544

ANTIFUNGAL DRUGS

Edited by Vassil St. Georgiev



*The New York Academy of Sciences
New York, New York
1988*

ACRUX DDS PTY LTD. et al.
EXHIBIT 1514

ANAL

Copyright © 1988 by the New York Academy of Sciences. All rights reserved. Under the provisions of the United States Copyright Act of 1976, individual readers of the Annals are permitted to make fair use of the material in them for teaching or research. Permission is granted to quote from the Annals provided that the customary acknowledgment is made of the source. Material in the Annals may be republished only by permission of the Academy. Address inquiries to the Executive Editor at the New York Academy of Sciences.

Copying fees: For each copy of an article made beyond the free copying permitted under Section 107 or 108 of the 1976 Copyright Act, a fee should be paid through the Copyright Clearance Center, 21 Congress Street, Salem, MA 01970. For articles of more than 3 pages, the copying fee is \$1.75.

⊗ The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences—Permanence of Paper for Printed Library Materials, ANSI Z39.48-1984.

Library of Congress Cataloging-in-Publication Data

Antifungal drugs / edited by Vassil St. Georgiev.

p. cm.—(Annals of the New York Academy of Sciences, ISSN 0077-8923; v. 544)

Contributions presented at the First International Conference on Drug Research in Immunologic and Infectious Diseases, held in Garden City, N.Y., on Oct. 8-10, 1987 and sponsored by the New York Academy of Sciences.

Includes bibliographies and index.

ISBN 0-89766-510-4 (alk. paper).—ISBN 0-89766-511-2 (pbk.: alk. paper)

1. Antifungal agents—Congresses. 2. Mycoses—Chemotherapy—Evaluation—Congresses. I. Georgiev, Vassil St. II. International Conference on Drug Research in Immunologic and Infectious Diseases (1st: 1987: Garden City, N.Y.) III. New York Academy of Sciences. IV. Series.

[DNLM: 1. Antifungal Agents—congresses. 2. Fungi—drug effects—congresses. 3. Mycoses—drug therapy—congresses. W1 AN626YL v. 544/QV 252 A629 1987] Q11.N5 vol. 544

[RM410]

500 s—dc 19

[616.9'69061]

DNLM/DLC

for Library of Congress

88-38918

CIP

Q
11
N45
v.544
BIOL

PCP

Printed in the United States of America

ISBN 0-89766-510-4 (cloth)

ISBN 0-89766-511-2 (paper)

ISSN 0077-8923

BSD
2-15-89

SD 2/13/89 jul

Volume 544
December 14, 1988

ANTIFUNGAL DRUGS^a

Editor and Conference Chairman
VASSIL ST. GEORGIEV

Conference Cochairmen
HIDEYO YAMAGUCHI and C. RICHARD KINSOLVING

Session Chairs
JOHN E. BENNETT, JEROME BIRNBAUM, DAVID J. DRUTZ, MARVIN GORMAN,
ARNOLD L. LENTNEK, and DINU RANE

CONTENTS

Fungal Infections and the Search for Novel Antifungal Agents: Opening Remarks. <i>By</i> VASSIL ST. GEORGIEV.....	1
Part I. Design, Synthesis, and Structure-Activity Relationships of Antifungal Agents	
Design and Evaluation of a Systemically Active Agent, Fluconazole. <i>By</i> K. RICHARDSON, K. COOPER, M. S. MARRIOTT, M. H. TARBIT, P. F. TROKE, and P. J. WHITTLE.....	4
Synthesis of Antifungal Imidazoles and Triazoles. <i>By</i> MASARU OGATA.....	12
Synthesis and Antifungal Activity of Novel Isoxazolidine Compounds. <i>By</i> GEORGE B. MULLEN, PATRICIA A. SWIFT, GRACE A. BENNETT, THOMAS R. DECORY, DAVID M. MARYNIAK, PETER G. DORMER, and VASSIL ST. GEORGIEV...	32
Synthesis and Structure-Activity Correlations within Allylamine Antimycotics. <i>By</i> ANTON STÜTZ.....	46
Structure-Activity Relationships of 2-(1 <i>H</i> -Imidazol-1-yl)vinyl Ethers: Route to the New Broad-Spectrum Antifungal Agent Omoconazole. <i>By</i> L. ZIRNGIBL, J. FISCHER, U. JAHN, and K. THIELE.....	63

^aAll of the contributions to this volume were presented at the **First International Conference on Drug Research in Immunologic and Infectious Diseases. Antifungal Drugs: Synthesis, Pre-clinical and Clinical Evaluation.** The conference, which was sponsored by the New York Academy of Sciences, was held in Garden City, New York, on October 8-10, 1987.

Vibunazole and Its Enantiomers: Synthesis, Antifungal Activity, and Pharmacokinetics. <i>By</i> WOLFGANG RITTER, GRAHAM HOLMWOOD, HANS-JUERGEN AHR, KLAUS DETZER, UDO KRAATZ, MANFRED PLEMPPEL, DIETRICH SCHERLING, and HANS-MARTIN SIEFERT.....	74
Synthesis and Structure-Activity Relationships of a Novel Antifungal Agent, ICI 195,739. <i>By</i> F. THOMAS BOYLE, DAVID J. GILMAN, MICHAEL B. GRAVESTOCK, and J. MICHAEL WARDLEWORTH	86
Pyrido[3,4- <i>e</i>]-1,2,4-triazines and Related Heterocycles as Potential Antifungal Agents. <i>By</i> M. F. REICH, P. F. FABIO, V. J. LEE, N. A. KUCK, and R. T. TESTA.....	101
Synthesis and Antifungal Properties of Dihydrobenzothiophene Azoles. <i>By</i> D. F. RANE, J. A. DESAI, D. LOEBENBERG, R. PARMEGIANI, and R. E. PIKE	105
Synthesis and Antifungal Properties of 14-Aminomethyl-Substituted Lanosterol Derivatives. <i>By</i> A. B. COOPER, J. J. WRIGHT, A. K. GANGULY, J. DESAI, D. LOEBENBERG, R. PARMEGIANI, and D. S. FEINGOLD.....	109

Part II. Structural Elucidation, Synthesis, and Antifungal Activity of Natural Products and Related Derivatives

Antifungal Substances from Marine Invertebrates. <i>By</i> NOBUHIRO FUSETANI	113
The Galbonolides: Novel, Powerful Antifungal Macrolides from <i>Streptomyces galbus</i> ssp. <i>eurithermus</i> . <i>By</i> HANS ACHENBACH, ANDREAS MÜHLENFELD, URSULA FAUTH, and HANS ZÄHNER	128
Antifungal Proteins from Plants. <i>By</i> WALDEN K. ROBERTS, BRIDGET E. LAUE, and CLAUDE P. SELITRENNIKOFF	141
Synthesis and Evaluation of LY121019, a Member of a Series of Semisynthetic Analogues of the Antifungal Lipopeptide Echinocandin B. <i>By</i> M. DEBONO, B. J. ABBOTT, J. R. TURNER, L. C. HOWARD, R. S. GORDEE, A. S. HUNT, M. BARNHART, R. M. MOLLOY, K. E. WILLARD, D. FUKUDA, T. F. BUTLER, and D. J. ZECKNER	152
Amphotericin B: Synthesis of Its Aglycone (Amphoterionolide B) and Degradation. <i>By</i> SATORU MASAMUNE.....	168
Hydroxamic Acid Antimycotic Antibiotics: A New Group of Antibiotics. <i>By</i> YOSHIO INOUE, HIROMASA OKADA, and SHOSHIRO NAKAMURA.....	180

L-660,631, a New Antifungal Agent. <i>By</i> A. J. KEMPF, O. D. HENSENS, R. E. SCHWARTZ, R. S. SYKES, K. E. WILSON, C. F. WICHMANN, D. L. ZINK, L. ZITANO, and S. MOCHALES	183
Novel Antifungal Antibiotic BMY-28567: Structural Study and Biological Activities. <i>By</i> TOSHIKAZU OKI, KYOICHIRO SAITOH, KOZO TOMATSU, KOJI TOMITA, MASATAKA KONISHI, and HIROSHI KAWAGUCHI	184
RI-331, a New Antifungal Antibiotic. <i>By</i> HIDEYO YAMAGUCHI, KATSUHISA UCHIDA, TAMIO HIRATANI, TAKATOSHI NAGATE, NAOHARU WATANABE, and SADATOSHI OMURA	188

Part III. Biochemical Studies and Mechanism of Action of Antifungal Agents

Mode of Action Studies: Basis for the Search of New Antifungal Drugs. <i>By</i> HUGO VANDEN BOSSCHE, PATRICK MARICHAL, JOS GORRENS, HUGO GEERTS, and PAUL A. J. JANSSEN	191
Mechanism of Action and Biochemical Selectivity of Allylamine Antimycotic Agents. <i>By</i> NEIL S. RYDER	208
Mode of Action of Morpholine Derivatives. <i>By</i> ANNEMARIE POLAK	221
Mode of Action of L-660,631 in <i>Candida albicans</i> . <i>By</i> JANET C. ONISHI, GEORGE K. ABRUZZO, ROBERT A. FROMTLING, GEORGE M. GARRITY, JAMES A. MILLIGAN, BARBARA A. PELAK, and WALTER ROZDILSKY	229
Mode of Action of β -Lactone 1233A in <i>Candida albicans</i> . <i>By</i> JANET C. ONISHI, GEORGE K. ABRUZZO, ROBERT A. FROMTLING, GEORGE M. GARRITY, JAMES A. MILLIGAN, BARBARA A. PELAK, WALTER ROZDILSKY, and BARBARA WEISSBERGER	230
Biochemical Studies with a Novel Antifungal Agent, ICI 195,739. <i>By</i> KEITH BARRETT-BEE, JOYCE LEES, PHILIP PINDER, JULIE CAMPBELL, and LORRAINE NEWBOULT	231
Drug Resistance in <i>Candida albicans</i> and <i>Candida glabrata</i> . <i>By</i> DAVID KERRIDGE, MARCO FASOLI, and FRANCES J. WAYMAN	245
Isolation and Characterization of Fluoropyrimidine-Resistant Mutants in Two <i>Candida</i> Species. <i>By</i> MARCO FASOLI and DAVID KERRIDGE	260

Part IV. Preclinical Evaluation of Antifungal Agents

Role of Animal and Human Pharmacology in Antifungal Drug Design. <i>By</i> GEERT CAUWENBERGH and JAN VAN CUTSEM	264
---	-----

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.